Result: Taken together, the missense mutations, Discussion: Higher infectivity of the SARS-CoV-2 variants is associated with increased in binding affinity between spike protein and ACE2 due to K417N, E484K, N439K and N501Y mutations in the RBD of the spike protein.
Discussion: While N501Y mutation alone enhanced spike RBD-ACE2 affinity, combination of K417N, E484K and N501Y mutations in B.1.351 lineage resulted in noticeable conformational changes in RBD when bound to ACE2.
Spike Gene Evolution and Immune Escape Mutations in Patients with Mild or Moderate Forms of COVID-19 and Treated with Monoclonal Antibodies Therapies.
Method: For each sample, screening of the E484K mutation was performed with a real-time PCR (TIB MOLBIOL VirSNiP Assay 484K, ref: 53-0789).
Result: At baseline, the E484K mutation was detected in only one sample issued from patient P6, and Sanger sequencing confirmed the presence of a Variant of Concern (VOC), the Gamma (20J/501Y.V3) variant.
Discussion: Our results also corroborate in vitro results observed under selective pressure from bamlanivimab, with the emergence of immune escape mutations, such as E484K and Q493R/K.
Characterization of a Broadly Neutralizing Monoclonal Antibody against SARS-CoV-2 Variants.
Introduction: It has been reported that several mutations in the SARS-CoV-2 RBM, such as N439K, L452R, S477N, T478K, E484K, S494P, N501Y, and A502S, have increased the infectivity and stability of SARS-CoV-2.
Discussion: However, a reduced binding efficacy was observed against variants (Beta, Kappa, and Gamma) containing amino acid mutation at E484K or Q (Table 1).
Rapid SARS-CoV-2 Intra-Host and Within-Household Emergence of Novel Haplotypes.
Introduction: Another mutation of note is E484K, which is found in the Beta and Gamma variants of concern and is related to a decrease in the susceptibility to monoclonal antibodies and convalescent plasma.
Allosteric Determinants of the SARS-CoV-2 Spike Protein Binding with Nanobodies: Examining Mechanisms of Mutational Escape and Sensitivity of the Omicron Variant.
PMID: 35216287
2022
International journal of molecular sciences
Introduction: Neutralization of SARS-CoV-2 by low-picomolar and mutation-tolerant VHH nanobodies that bind synergistically to the opposite sides of the RBD produced a binding avidity effect unaffected by immune-escape mutants K417N/T, E484K, N501Y, and L452R.
Introduction: The detection of common mutational changes such as D614G, E484K, N501Y, and K417N that are shared among major circulating variants B.1.1.7, B.1.351, and B.1.1.28/P.1 indicated that these positions could be particularly critical for modulation of the SARS-CoV-2 S protein responses.
Introduction: These studies identified a group of common resistant mutations in
SARS-CoV-2 Omicron Spike recognition by plasma from individuals receiving BNT162b2 mRNA vaccination with a 16-week interval between doses.
Introduction: The accumulation of E484K and K417N/T mutations along with N501Y in the receptor binding domain (RBD) led to the emergence of Beta (B.1.351) and Gamma (P.1) lineages, which rapidly spread worldwide.
Discussion: Previous in vitro studies already showed the association of some of these mutations with increased infectivity, ACE2 interaction (N501Y, P681H), or immune evasion (K417N, N440K, G446S, S477N, E484A/K, Q493R).
A Detailed Overview of Immune Escape, Antibody Escape, Partial Vaccine Escape of SARS-CoV-2 and Their Emerging Variants With Escape Mutations.
Abstract: Simultaneously we have discussed the significant mutations related to emerging variants and immune escape, such as mutations in the RBD region (N439K, L452R, E484K, N501Y, K444R) and other parts (D614G, P681R) of the S-glycoprotein.
Introduction: <
Introduction: 4.1.3.4 E484K.
Introduction: Among these four mutations, the E484K mutation is a very significant mutation among these mutations.
Introduction: At the same time, the E484K mutation is accountable for class 2 antibody escape.
Table: E484K
Molecular and Epidemiological Characterization of Emerging Immune-Escape Variants of SARS-CoV-2.
Result: Delta + E484K + N501Y and Mu showed a pattern similar to that of Beta, with 73.8% and 78.6% of the samples strongly neutralized, respectively.
Result: Delta + E484K + N501Y was detected only in Turkey from week 26, Mu was prevalent in South America from week 14, and C.1.2 was prevalent in South Africa from week 26 (Figure 4).
Result: Etesevimab was still effective against Delta, but the effect was reduced in Delta + E484K + N501Y.
Result: However, at 6 months after vaccination, strong neutralizing activity was significantly reduced against all mutant strains, ranging from the highest (60.2%) in the Lambda to the lowest in the Delta + E484K + N501Y variant (15.3 %) (Figure 3).
Emergence and onward transmission of a SARS-CoV-2 E484K variant among household contacts of a bamlanivimab-treated patient.
PMID: 35231807
2022
Diagnostic microbiology and infectious disease
Abstract: Here we describe a newly acquired spike E484K mutation detected within the B.1.311 lineage.
Abstract: The timing and patterns of spread were consistent with de novo emergence of this E484K variant in the bamlanivimab-treated index patient.
Result: Accordingly, while we cannot exclude the possibility that this E484K substrain was pre-existing at a very low level, our intense yet incomplete surveillance did not find any evidence of it.
Result: Firstly, despite widespread regional surveillance, we did not detect this B.1.311/E484K lineage in any patient except those associated with this particular household.
Result: In addition to the E484K described in our Minnesota cluster, we found examples in New York (1 sequenced case) and California (2 case
SARS-CoV-2 Beta and Delta variants trigger Fc effector function with increased cross-reactivity.
Method: For ELISA, ADCP and ADCD assays, SARS-CoV-2 original and Beta variant full spike (L18F
Result: As for full spike (Figure S1), CR3022 ADCC against the RBD was unaffected by Beta RBD mutations (K417N, E484K, and N501Y), while ADCC mediated by P2B-2F6 was abrogated (Figure 3A).
Table: E484K
Figure: (A) ADCC of monoclonal antibodies CR3022, P2B-2FB, and palivizumab shown as RLU of signaling through FcgammaRIIIa expressing cells and crosslinking of original (white) or Beta (red) (K417N, E484K, and N501Y) RBD protein.
SARS_CoV_2 mutation literature information.
PMID: 
2022
PloS one
Browser Board
Co-occurred Entities
Filtrator
ViMRT